$EXEL
EXELIXIS, INC. Stock $exel

$exel Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000093976715000102 Filed on November 10, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$9.938M	$9.854M	$6.291M
YoY Change	35.16%	56.64%	15.09%
Cost Of Revenue	$1.000M	$1.420M	$573.0K
YoY Change	42.86%	147.82%	97.59%
Gross Profit	$8.915M	$8.434M	$5.718M
YoY Change	33.68%	47.5%	10.47%
Gross Profit Margin	89.71%	85.59%	90.89%
Selling, General & Admin	$17.10M	$17.84M	$9.906M
YoY Change	74.49%	80.11%	-27.15%
% of Gross Profit	191.81%	211.55%	173.24%
Research & Development	$23.50M	$26.09M	$43.63M
YoY Change	-40.81%	-40.2%	-7.87%
% of Gross Profit	263.6%	309.35%	762.99%
Depreciation & Amortization	$300.0K	$400.0K	$1.900M
YoY Change	-150.0%	-78.95%	137.5%
% of Gross Profit	3.37%	4.74%	33.23%
Operating Expenses	$40.60M	$45.64M	$57.87M
YoY Change	-17.81%	-21.14%	-5.73%
Operating Profit	-$31.60M	-$35.78M	-$51.57M
YoY Change	-31.61%	-30.62%	-7.76%
Interest Expense	-$9.900M	$10.04M	$12.28M
YoY Change	-16.81%	-18.28%	7.45%
% of Operating Profit
Other Income/Expense, Net		-$9.761M	-$10.99M
YoY Change		-11.15%	-2.01%
Pretax Income	-$41.50M	-$45.50M	-$62.60M
YoY Change	-28.57%	-27.32%	-6.74%
Income Tax	$100.0K
% Of Pretax Income
Net Earnings	-$41.57M	-$45.54M	-$62.56M
YoY Change	-28.27%	-27.2%	-6.8%
Net Earnings / Revenue	-418.27%	-462.17%	-994.44%
Basic Earnings Per Share
Diluted Earnings Per Share	-$182.9K	-$209.1K	-$320.9K
COMMON SHARES
Basic Shares Outstanding	227.2M shares	225.4M shares	195.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$167.1M	$197.8M	$192.0M
YoY Change	15.8%	3.02%	-31.23%
Cash & Equivalents	$141.6M	$145.6M	$100.1M
Short-Term Investments	$25.40M	$52.20M	$91.90M
Other Short-Term Assets	$3.800M	$3.900M	$20.10M
YoY Change	-75.8%	-80.6%	0.5%
Inventory	$2.616M	$2.121M	$3.876M
Prepaid Expenses
Receivables	$5.200M	$3.500M	$4.700M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$178.7M	$207.4M	$220.7M
YoY Change	6.83%	-6.04%	-27.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.434M	$1.448M	$2.928M
YoY Change	-41.04%	-50.55%	-46.96%
Goodwill	$63.68M	$63.68M	$63.68M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$83.60M	$81.60M	$84.60M
YoY Change	2.45%	-3.55%	-46.25%
Other Assets	$2.309M	$6.508M	$7.101M
YoY Change	-36.72%	-8.35%	-2.73%
Total Long-Term Assets	$153.7M	$155.9M	$163.0M
YoY Change	-1.51%	-4.35%	-34.75%
TOTAL ASSETS
Total Short-Term Assets	$178.7M	$207.4M	$220.7M
Total Long-Term Assets	$153.7M	$155.9M	$163.0M
Total Assets	$332.3M	$363.2M	$383.7M
YoY Change	2.81%	-5.32%	-30.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.401M	$2.256M	$3.362M
YoY Change	-0.19%	-32.9%	-5.54%
Accrued Expenses	$18.07M	$29.79M	$45.10M
YoY Change	-56.5%	-33.95%	28.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$450.0K	$97.25M
YoY Change	-100.0%	-99.54%	701.95%
Total Short-Term Liabilities	$52.25M	$55.92M	$173.9M
YoY Change	-69.34%	-67.84%	123.31%
LONG-TERM LIABILITIES
Long-Term Debt	$417.9M	$377.4M	$258.0M
YoY Change	61.28%	46.31%	-21.7%
Other Long-Term Liabilities	$2.960M	$1.881M	$4.772M
YoY Change	-29.0%	-60.58%	-16.66%
Total Long-Term Liabilities	$420.9M	$379.3M	$262.7M
YoY Change	59.85%	44.37%	-21.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$52.25M	$55.92M	$173.9M
Total Long-Term Liabilities	$420.9M	$379.3M	$262.7M
Total Liabilities	$473.1M	$437.5M	$442.2M
YoY Change	-1.96%	-1.06%	4.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.913B	-$1.893B	-$1.709B
YoY Change	9.24%	10.77%	19.7%
Common Stock	$228.0K	$225.0K	$195.0K
YoY Change	16.33%	15.38%	5.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$104.3M	-$74.20M	-$58.50M
YoY Change
Total Liabilities & Shareholders Equity	$332.3M	$363.2M	$383.7M
YoY Change	2.81%	-5.32%	-30.99%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$41.57M	-$45.54M	-$62.56M
YoY Change	-28.27%	-27.2%	-6.8%
Depreciation, Depletion And Amortization	$300.0K	$400.0K	$1.900M
YoY Change	-150.0%	-78.95%	137.5%
Cash From Operating Activities	-$35.40M	-$34.30M	-$58.00M
YoY Change	-29.2%	-40.86%	1.75%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	$0.00	-$200.0K
YoY Change		-100.0%	-71.43%
Acquisitions
YoY Change
Other Investing Activities	$24.30M	-$31.50M	$11.20M
YoY Change	-19.54%	-381.25%	-40.11%
Cash From Investing Activities	$24.00M	-$31.50M	$11.20M
YoY Change	-20.27%	-381.25%	-37.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$145.6M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.400M	149.4M	-300.0K
YoY Change	7300.0%	-49900.0%	-62.5%
NET CHANGE
Cash From Operating Activities	-35.40M	-34.30M	-58.00M
Cash From Investing Activities	24.00M	-31.50M	11.20M
Cash From Financing Activities	7.400M	149.4M	-300.0K
Net Change In Cash	-4.000M	83.60M	-47.10M
YoY Change	-79.8%	-277.49%	18.34%
FREE CASH FLOW
Cash From Operating Activities	-$35.40M	-$34.30M	-$58.00M
Capital Expenditures	-$300.0K	$0.00	-$200.0K
Free Cash Flow	-$35.10M	-$34.30M	-$57.80M
YoY Change	-29.8%	-40.66%	2.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--01-01
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-10-02
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000939767
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	227216551	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	EXELIXIS, INC.
	dei	Trading Symbol TradingSymbol	exel
CY2014Q4	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	242760000	USD
CY2015Q3	exel	Cash Cash Equivalentsand Availableforsale Securities CashCashEquivalentsandAvailableforsaleSecurities	282061000	USD
CY2014Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	242772000	USD
CY2015Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Amortized Cost Basis CashCashEquivalentsandAvailableforsaleSecuritiesAmortizedCostBasis	281993000	USD
CY2014Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	145000	USD
CY2015Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Gain Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedGainAccumulatedinInvestments	81000	USD
CY2014Q4	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	157000	USD
CY2015Q3	exel	Cash Cash Equivalentsand Availableforsale Securities Gross Unrealized Loss Accumulatedin Investments CashCashEquivalentsandAvailableforsaleSecuritiesGrossUnrealizedLossAccumulatedinInvestments	13000	USD
	exel	Debt Collateral Number Of Affiliate Banks DebtCollateralNumberOfAffiliateBanks	1	affiliate
	exel	Debt Collateral Number Of Required Investment Accounts DebtCollateralNumberOfRequiredInvestmentAccounts	1	account
CY2015Q3	exel	Numberof Trialsin Process NumberofTrialsinProcess	40	trial
	exel	Proceeds From Exercise Of Stock Options And Warrants Net Of Repurchases ProceedsFromExerciseOfStockOptionsAndWarrantsNetOfRepurchases	120000	USD
	exel	Proceeds From Exercise Of Stock Options And Warrants Net Of Repurchases ProceedsFromExerciseOfStockOptionsAndWarrantsNetOfRepurchases	3787000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6413000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2256000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3350000	USD
CY2015Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3725000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41545000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29788000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-121000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1652400000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1818988000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	714000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8454000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12026000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15420000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	21826000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	20194000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	110977000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	120339000	shares
CY2014Q4	us-gaap	Assets Assets	327960000	USD
CY2015Q3	us-gaap	Assets Assets	363241000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	167241000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	207351000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	238286000	USD
CY2015Q3	us-gaap	Assets Fair Value Disclosure Recurring AssetsFairValueDisclosureRecurring	279862000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	238286000	USD
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	279862000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	145000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	80000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	157000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	238298000	USD
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	279795000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	13000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	27900000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	29186000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	250676000	USD
CY2015Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	14	investment
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103978000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100065000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80395000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145642000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3913000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	65247000	USD
CY2015Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	197800000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	195895769	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	226154354	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	195895769	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	226154354	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	196000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	225000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62713000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-210711000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47431000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-126016000	USD
CY2014Q3	us-gaap	Contracts Revenue ContractsRevenue	0	USD
	us-gaap	Contracts Revenue ContractsRevenue	0	USD
CY2015Q3	us-gaap	Contracts Revenue ContractsRevenue	3000000	USD
	us-gaap	Contracts Revenue ContractsRevenue	3000000	USD
CY2014Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	98880000	USD
CY2015Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	450000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	182395000	USD
CY2015Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	297436000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	573000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1359000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1420000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2872000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2583000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3014000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1063000	USD
CY2014Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	921000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.09
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1916000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	549000	USD
CY2014	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P371D
	us-gaap	Fiscal Period Duration FiscalPeriodDuration	P364D
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	100000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	100000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	838000	USD
	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	95000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	63684000	USD
CY2015Q3	us-gaap	Goodwill Goodwill	63684000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	781000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1034000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11600000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-162000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	10144000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-11757000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-131000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2583000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	986000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-259000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-756000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1367000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2834000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	108000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-20397000	USD
	us-gaap	Increase Decrease In Restricted Cash And Investments IncreaseDecreaseInRestrictedCashAndInvestments	-16754000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-2705000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-5731000	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	12282000	USD
	us-gaap	Interest Expense InterestExpense	36125000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	12059000	USD
	us-gaap	Interest Expense InterestExpense	36421000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	559000	USD
CY2015Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	745000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	4522000	USD
CY2015Q3	us-gaap	Inventory Gross InventoryGross	4011000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	2381000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	2121000	USD
CY2014Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	2141000	USD
CY2015Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	1890000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1118000	USD
CY2015Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1063000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	2845000	USD
CY2015Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	2203000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1100000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	442789000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	437469000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	327960000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	363241000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	171860000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	55922000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	361656000	USD
CY2015Q3	us-gaap	Long Term Debt LongTermDebt	377886000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	99261000	USD
CY2015Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	450000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	262395000	USD
CY2015Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	377436000	USD
CY2014Q4	us-gaap	Long Term Investments LongTermInvestments	81579000	USD
CY2015Q3	us-gaap	Long Term Investments LongTermInvestments	81600000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	80000000	USD
CY2015Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	80000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	65362000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	145331000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	116154000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	26068000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-185429000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-106152000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-62560000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-210589000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-47564000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-126096000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10986000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-32339000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11783000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36275000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	381000	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	0	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	57865000	USD
	us-gaap	Operating Expenses OperatingExpenses	196008000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-51574000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-178250000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	45635000	USD
	us-gaap	Operating Expenses OperatingExpenses	117055000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35781000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89821000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12282000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15969000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	8340000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6508000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-153000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-122000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	133000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	80000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4169000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1881000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3602000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1338000	USD
CY2014Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1296000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3786000	USD
CY2015Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	276000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	146000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1890000	USD
CY2015Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	109237000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	119692000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	452000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	114000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	8184000	USD
	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	2616000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3481000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3949000	USD
CY2015Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	145600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	75646000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	145651000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	212506000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	130341000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-11333000	USD
	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-4381000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	838000	USD
	us-gaap	Proceeds From Sale And Maturity Of Other Investments ProceedsFromSaleAndMaturityOfOtherInvestments	95000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	286000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1300000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	929000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	274000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2432000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1448000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	4882000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149451000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26091000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72879000	USD
CY2015Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	3470000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	43628000	USD
CY2015Q3	us-gaap	Share Price SharePrice	5.40
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	29649000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y10M20D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y9M29D
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	63890000	USD
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	52169000	USD
CY2015Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	28750000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	875504	shares
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-114829000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	12212000	USD
CY2015Q3	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	0	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	4684000	USD
CY2015Q3	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	2650000	USD
CY2014Q3	us-gaap	Restructuring Charges RestructuringCharges	3758000	USD
	us-gaap	Restructuring Charges RestructuringCharges	4135000	USD
CY2015Q3	us-gaap	Restructuring Charges RestructuringCharges	282000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1142000	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	667000	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	0	USD
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6426000	USD
CY2015Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	3734000	USD
CY2014Q4	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	4365000	USD
CY2015Q3	us-gaap	Restructuring Reserve Noncurrent RestructuringReserveNoncurrent	2230000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1767304000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1893400000	USD
CY2014Q3	us-gaap	Revenues Revenues	6291000	USD
	us-gaap	Revenues Revenues	17758000	USD
CY2015Q3	us-gaap	Revenues Revenues	9854000	USD
	us-gaap	Revenues Revenues	27234000	USD
	us-gaap	Sales Discounts Returns And Allowances Goods SalesDiscountsReturnsAndAllowancesGoods	1800000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	64400000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6291000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17758000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	6854000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24234000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9906000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41063000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	17842000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40162000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8454000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	15420000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	18385413	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4403827	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	924890	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	8505300	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	58332000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	27811992	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	30113071	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.00
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.48
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.33
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.52
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.70
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	193855000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	217587000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	203153000	shares
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-74228000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	195126000	shares
	us-gaap	Fiscal Period FiscalPeriod	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exelixis adopted a 52- or 53-week fiscal year that generally ends on the Friday closest to December 31st. Fiscal year 2015, a 52-week year, will end on </font><font style="font-family:inherit;font-size:10pt;">January 1, 2016</font><font style="font-family:inherit;font-size:10pt;">, and fiscal year 2014, a 53-week year, ended on </font><font style="font-family:inherit;font-size:10pt;">January 2, 2015</font><font style="font-family:inherit;font-size:10pt;">. For convenience, references in this report as of and for the fiscal periods ended </font><font style="font-family:inherit;font-size:10pt;">October 2, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">September 26, 2014</font><font style="font-family:inherit;font-size:10pt;">, and as of and for the fiscal years ended </font><font style="font-family:inherit;font-size:10pt;">January 1, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">January 2, 2015</font><font style="font-family:inherit;font-size:10pt;">, are indicated as being as of and for the periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">September 30, 2014</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">December 31, 2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">The preparation of our consolidated financial statements is in conformity with accounting principles generally accepted in the United States which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to, those related to inventory, revenue recognition, valuation of long-lived assets, certain accrued liabilities including clinical trial accruals and restructuring liability, valuation of warrants, share-based compensation and the valuation of the debt and equity components of our convertible debt at issuance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. </font></font><font style="font-family:inherit;font-size:10pt;">Actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>

Files In Submission

Name	View Source	Status
0000939767-15-000102-index-headers.html	Edgar Link	pending
0000939767-15-000102-index.html	Edgar Link	pending
0000939767-15-000102.txt	Edgar Link	pending
0000939767-15-000102-xbrl.zip	Edgar Link	pending
exel-20151002.xml	Edgar Link	completed
exel-20151002.xsd	Edgar Link	pending
exel-20151002_cal.xml	Edgar Link	unprocessable
exel-20151002_def.xml	Edgar Link	unprocessable
exel-20151002_lab.xml	Edgar Link	unprocessable
exel-20151002_pre.xml	Edgar Link	unprocessable
exel2015093010-q.htm	Edgar Link	pending
exel20150930exhibit105.htm	Edgar Link	pending
exel20150930exhibit121.htm	Edgar Link	pending
exel20150930exhibit311.htm	Edgar Link	pending
exel20150930exhibit312.htm	Edgar Link	pending
exel20150930exhibit321.htm	Edgar Link	pending
exel20150930exhibit45.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EXEL
EXELIXIS, INC. Stock $exel

2015 Q4 Form 10-Q Financial Statement

#000093976715000102 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL EXELIXIS, INC. Stock $exel

2015 Q4 Form 10-Q Financial Statement

#000093976715000102 Filed on November 10, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EXEL
EXELIXIS, INC. Stock $exel